#United States #New York #Securities Fraud #Pomerantz LLP #Soleno Therapeutics

Pomerantz Law Firm's Investigation into Soleno Therapeutics

Pomerantz LLP, a well-regarded law firm specializing in corporate and securities litigation, has embarked on an investigation concerning allegations of securities fraud related to Soleno Therapeutics, Inc. (NASDAQ: SLNO). The inquiry primarily aims to determine whether Soleno and several of its executives engaged in illegal business practices that might have adversely impacted investors. This investigation is particularly pertinent for stakeholders interested in the potential ramifications for the firm and its operations.

Overview of the Investigation

The investigation follows a distressing report by Scorpion Capital published on August 15, 2025. In this report, Scorpion labeled Soleno’s sole product, Vykat XR, as excessively priced and flagged safety concerns regarding its usage in children. This disclosure led to a significant drop in Soleno’s stock price, which fell by $5.73, or 7.41%, closing at $71.63 per share on the same day.

However, the situation escalated further on November 4, 2025, when Soleno's quarterly earnings call revealed alarming statistics regarding Vykat XR. The company reported that approximately 8% of children using the product discontinued treatment due to adverse effects. The CEO of Soleno noted that the company had experienced a disrupted launch trajectory for Vykat XR due to the negative media stemming from the Scorpion report. Following this revelation, Soleno's stock plummeted even further, dropping by $16.98 (-26.59%), closing at $46.87 the next day.

Investors who believe they have been adversely affected by these developments are encouraged by Pomerantz LLP to reach out for guidance. The firm is committed to elucidating the specifics surrounding the allegations and providing a platform for affected investors to seek recourse.

Background of Pomerantz LLP

Pomerantz LLP is recognized as a leading firm in the arena of corporate, securities, and antitrust class actions. Founded over 85 years ago by Abraham L. Pomerantz, the firm has maintained its reputation by continuously advocating for victims of securities fraud and corporate misconduct. Pomerantz has successfully recovered numerous multimillion-dollar awards for its clients, underscoring its expertise and commitment to justice in the financial sector. This latest investigation into Soleno Therapeutics adds another chapter to its long history of defending investor rights.

For more information and to explore possible participation in the investigation or class action, investors can contact Danielle Peyton at Pomerantz LLP via email at [email protected] or by phone at 646-581-9980, ext. 7980. Investors are urged to act promptly as legal timelines may affect their ability to seek claims.

This investigation serves as a reminder of the complexities surrounding the biotech industry, particularly regarding the accountability of therapeutic companies in ensuring the safety and efficacy of their products, especially those intended for vulnerable populations like children. With significant financial implications at stake, the outcomes of Pomerantz's inquiry could have lasting impacts on Soleno Therapeutics and its stakeholders.